• Patricia Guilabert, Lars Asmis, Vicente Cortina, Joan P Barret, and Maria J Colomina.
• Department of Anesthesia and Critical Care, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain - patricia.guilabert@gmail.com.
• Minerva Anestesiol. 2022 Mar 1; 88 (3): 156-165.

AbstractFactor XIII (FXIII) is the final factor in the coagulation cascade. It converts soluble fibrin monomers into a stable fibrin clot, prevents premature degradation of fibrin, participates in wound healing, and helps prevent the loss of the endothelial barrier function. FXIII deficiency is believed to be rare, and this may explain why clinicians do not routinely take it into consideration. Congenital FXIII deficiency is a rare disease with a reported prevalence of 1 per million. However, the prevalence of acquired FXIII deficiency is much higher. Acquired forms have been described in patients with decreased hepatic or bone marrow synthesis, overconsumption and increased degradation by autoantibodies. This review offers guidance on how to suspect and diagnose FXIII deficiency in both the preoperative consultation and different surgical settings. We also analyze current scientific evidence in order to clarify when and why this clinical situation should be suspected, and how it may be treated.

21 keywords...

hide…